LONDON (AFP) - Pharmaceutical giant AstraZeneca on Tuesday said it would shut research and development sites in Britain and Sweden and reduce US operations as part of previously announced plans to axe 8,000 jobs.

RELATED NEWS:
• AstraZeneca to axe 8,000 jobs worldwide

The company had in January said that it was looking to cut 8,000 jobs worldwide by 2014, including 3,500 R&D; positions.

On Tuesday it said it would close an R&D; centre in Leicestershire, central England, and a smaller site in Cambridge, close to London.

It added that it would shut a research site in Lund, Sweden, and reduce activities at a facility in Wilmington, Delaware.

"AstraZeneca today shared with its employees further details of proposals designed to improve the productivity of its global research and development organisation," the group said in a statement.

"The proposed changes, first outlined at the end of January, include focusing research efforts on a smaller number of disease areas and consolidating activities onto a reduced global footprint through the merger of some sites. Some of our sites will close," it added.

Last Updated (Wednesday, 03 March 2010 08:43)

 

Comments 

 
#1 Jake 2010-03-04 16:30
It comes as no shock to campaigners that AstraZeneca may treat it's workforce as expendable, as they do this to the animals everyday, using the most exposed animal lab in the world – HLS.
It won't be David Brennan, CEO taking the fall but the everyday AstraZeneca employees and smaller R&D; subsidiary employees – like the Cambridge,UK based KuDOs' staff.
If you are an ex-KuDOs Pharma employee and have something to share please see:
http://kudossolidarity.tk/
Quote
 
PDF Print E-mail